Barclays Sets $923 Price Target for Regeneron as Dupixent Sales Surge 34%
Barclays assigned a $923 price target for Regeneron Pharmaceuticals, implying 20.66% upside from its $764.93 closing price. Dupixent sales rose 34% last quarter and Eylea HD also contributed to growth, supporting the company’s $79.48 billion valuation despite a recent 2.87% stock decline.
1. Analyst Price Target and Upside Potential
Barclays assigned a $923 price target to Regeneron shares, indicating a potential 20.66% gain from the recent $764.93 closing price. Hitting this target would raise the company’s market capitalization to approximately $79.48 billion.
2. Dupixent and Eylea HD Drive Revenue Growth
Dupixent achieved a 34% year-over-year sales increase in the latest quarter, driven by strong demand in inflammatory conditions. Eylea HD also recorded notable gains in retinal disease treatments, reinforcing Regeneron’s robust product portfolio.
3. Recent Stock Performance and Trading Metrics
Following the price target announcement, shares fell 2.87%, trading between $760.01 and $781.99 yesterday. The stock has ranged from a 52-week low of $476.49 to a high of $821.11 on a volume of 627,844 shares.